Catheter Precision IncVTAK
Price$0.15

Qualitative Analysis

Business overview

Business Overview

Catheter Precision, Inc. (NYSE American: VTAK) is an innovative medical technology company historically focused on the cardiac electrophysiology (EP) market. Its core medical device portfolio includes the VIVO™ (View Into Ventricular Onset) system, a non-invasive 3D cardiac mapping system that helps localize the origin of ventricular arrhythmias prior to EP procedures, and LockeT, a suture retention device designed to assist in wound closure and achieve rapid hemostasis after percutaneous venous punctures. In early 2026, the company executed a major strategic pivot by acquiring Fly Flyte, Inc. (operating as Flyte), an FAA-certified regional aviation operator utilizing AI technology and a fleet of Cirrus Vision Jets. Following this acquisition, Catheter Precision operates two distinct segments: cardiac electrophysiology and private aviation charter services. The company has announced plans to divest its FDA-cleared cardiac assets (VIVO and LockeT) to transition into a pure-play aviation business, aiming to unlock shareholder value through disciplined capital allocation.

Research as of 20 Jun 2026

Strategic Initiatives

Growth programs, investments, and their expected impact

AI-assisted
Dual-Engine Growth Strategy and Aviation PivotTransformation

Following the acquisition of Fly Flyte, Inc., the company expanded its operations into private aviation alongside its legacy cardiac electrophysiology segment. Over time, the company plans to divest its medical assets to become a pure-play regional aviation business.

Expected impact: Diversifies revenue streams immediately, scales the aviation fleet from one to three aircraft, and establishes a scalable, asset-backed regional air mobility platform.

Sign in / Sign up to read more
InvestmentFunded through a multi-tranche private placement of convertible preferred stock, raising an initial $1.85 million with options to raise up to $35.56 million.
TimelineInitiated in Q1 2026 with the acquisition of Flyte; ongoing transition throughout 2026.
Global Commercial Expansion of Electrophysiology ProductsExpansion

Expanding the global sales footprint of the VIVO 3D cardiac mapping system and LockeT vascular closure device through international regulatory approvals and distribution partnerships.

Expected impact: Drives product sales growth and clinical adoption. Recent milestones include securing a VIVO purchase order from the University Clinical Center Ljubljana in Slovenia.

Sign in / Sign up to read more
InvestmentSupported by legacy capital resources and multi-segment financing initiatives.
TimelineOngoing; expanded to 15 countries in early 2026.

Mergers, Acquisitions & Partnerships

Recent deals and strategic collaborations

AI-assisted

Recent Acquisitions

Fly Flyte, Inc. (and Ponderosa Air, LLC)$11.6M
Announced 9 Mar 2026

To acquire 100% ownership of Flyte (having previously acquired a 19.98% minority stake on February 17, 2026) and 100% of its FAA-certified Part 135 air carrier subsidiary, Ponderosa Air, LLC, establishing a scalable, technology-enabled regional aviation platform.

Financial impact: Contributed immediate service revenue of $184,000 in Q1 2026 and achieved a monthly revenue run rate of approximately $200,000 within 22 days post-acquisition.

Sign in / Sign up to read more
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.